The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00197782
: September 20, 2005
Last Update Posted
: March 28, 2012
Public Health England
Information provided by (Responsible Party):
Dr. Elizabeth Miller, Health Protection Agency, United Kingdom
To measure the magnitude and persistence of the antibody response to a booster dose of Hib conjugate vaccine given between 9 months and 4 years of age to UK children who had completed primary immunisation with 3 doses of Hib vaccine given at 2/3/4 months of age either as a combined D/T/wholecellpertussis/Hib or D/T/acellularpertussis/Hib vaccine.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
9 Months to 4 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Written informed consent from parent or legal guardian of the infant or child
Age >= 9 months and <4 years at recruitment
Eligible to receive a single dose of Hib vaccine as per the UK schedule
Receipt of three doses of Hib vaccine in infancy
History of Hib infection
History of severe local reaction that can be confidently related to a prior Hib immunisation
Deferral of vaccination if acute illness and/or temperature >38C on day of vaccination